Hoth Therapeutics Announces Expansion of Cancer Treatment Trial

Hoth Therapeutics Expands FDA Cleared Clinical Trial for Cancer Patients: An Urgent Call to Action.

Hoth Therapeutics, Inc. (NASDAQ: $HOTH) has announced the expansion of an FDA cleared first-in-human clinical trial for cancer patients of HT-001 at the University of Miami. This news could potentially change the landscape of cancer treatment and is a matter of urgent concern for all stakeholders involved.

The clinical trial, centered around HT-001, is a…